MX2009003542A - Metodos y composiciones con opalescencia reducida. - Google Patents
Metodos y composiciones con opalescencia reducida.Info
- Publication number
- MX2009003542A MX2009003542A MX2009003542A MX2009003542A MX2009003542A MX 2009003542 A MX2009003542 A MX 2009003542A MX 2009003542 A MX2009003542 A MX 2009003542A MX 2009003542 A MX2009003542 A MX 2009003542A MX 2009003542 A MX2009003542 A MX 2009003542A
- Authority
- MX
- Mexico
- Prior art keywords
- ionic strength
- aggregates
- antibody
- modification
- solutions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describen métodos para reducir la apariencia opalescente de una preparación proteínica que modifica la fuerza iónica de la preparación, así como composiciones, por ejemplo, composiciones farmacéuticas, de una proteína concentrada con una opalescencia disminuida. También se describen métodos de purificación que monitorizan y/o reducen las concentraciones de sal durante las etapas seleccionadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85165106P | 2006-10-12 | 2006-10-12 | |
PCT/US2007/021904 WO2008045563A2 (en) | 2006-10-12 | 2007-10-12 | Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009003542A true MX2009003542A (es) | 2009-04-15 |
Family
ID=39205011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009003542A MX2009003542A (es) | 2006-10-12 | 2007-10-12 | Metodos y composiciones con opalescencia reducida. |
Country Status (12)
Country | Link |
---|---|
US (1) | US7744890B2 (es) |
EP (1) | EP2076287A2 (es) |
JP (1) | JP2010506839A (es) |
KR (1) | KR20090069330A (es) |
CN (1) | CN101522219A (es) |
AU (1) | AU2007308145A1 (es) |
BR (1) | BRPI0719250A2 (es) |
CA (1) | CA2665423A1 (es) |
IL (1) | IL197778A0 (es) |
MX (1) | MX2009003542A (es) |
RU (1) | RU2009111138A (es) |
WO (1) | WO2008045563A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2665423A1 (en) | 2006-10-12 | 2008-04-17 | Wyeth | Methods and compositions with reduced opalescence |
EP2020240A1 (en) * | 2007-07-30 | 2009-02-04 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Methods and substances for the treatment of Alzheimer's |
WO2010000721A1 (en) | 2008-06-30 | 2010-01-07 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
CN102395597A (zh) * | 2009-03-11 | 2012-03-28 | 惠氏有限责任公司 | 纯化小模块免疫药物蛋白的方法 |
US8454956B2 (en) | 2009-08-31 | 2013-06-04 | National Cheng Kung University | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
EP2518084B1 (en) * | 2009-12-25 | 2016-11-30 | Sekisui Medical Co., Ltd. | Method for measuring human insulin and measurement reagent |
BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
CN105001335B (zh) | 2010-03-01 | 2019-10-25 | 拜耳医药保健有限公司 | 针对组织因子途径抑制剂(tfpi)的优化的单克隆抗体 |
WO2011147921A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
US9221904B2 (en) | 2012-07-19 | 2015-12-29 | National Cheng Kung University | Treatment of osteoarthritis using IL-20 antagonists |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
US8852588B2 (en) | 2012-08-07 | 2014-10-07 | National Cheng Kung University | Treating allergic airway disorders using anti-IL-20 receptor antibodies |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
EP3459539B1 (en) * | 2016-05-19 | 2021-06-09 | Everfront Biotech Inc. | Pharmaceutical composition for delaying the onset of and/or treating pulmonary fibrosis |
FI3761035T3 (fi) | 2016-08-18 | 2024-03-18 | Regeneron Pharma | Analyysi proteiinin itseassosiaatiomahdollisuuden määrittämiseksi käyttäen pitoisuudesta riippuvaa itseinteraktio-nanopartikkelispektroskopiaa |
CN107236038B (zh) * | 2017-06-20 | 2020-11-27 | 华兰生物工程股份有限公司 | 微晶纤维素提高蛋白质澄清度的方法及其产品和应用 |
JP7233980B2 (ja) * | 2019-03-08 | 2023-03-07 | キオクシア株式会社 | 粒子計測方法及び検出液 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4396608A (en) * | 1981-08-24 | 1983-08-02 | Cutter Laboratories | Intravenously injectable immune serum globulin |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB8628104D0 (en) * | 1986-11-25 | 1986-12-31 | Connaught Lab | Pasteurization of immunoglobin solutions |
EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
EP0403559A1 (en) | 1988-03-04 | 1990-12-27 | Cancer Research Campaign Technology Limited | Improvements relating to antigens |
EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
DE59010933D1 (de) | 1989-09-12 | 2003-05-08 | Hoffmann La Roche | TFN-bindende Proteine |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
ATE363532T1 (de) | 1991-03-01 | 2007-06-15 | Dyax Corp | Verfahren zur herstellung bindender miniproteine |
DE69233367T2 (de) | 1991-04-10 | 2005-05-25 | The Scripps Research Institute, La Jolla | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
CA2170352A1 (en) | 1993-08-27 | 1995-03-02 | Paul Anderson | Natural killer cell-specific antigen and antibodies that identify the same |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5516964A (en) | 1994-01-21 | 1996-05-14 | Sun Company, Inc. (R&M) | Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal |
JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク. | 免疫したゼノマウス(XenoMouse)に由来するヒト抗体 |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1997008320A1 (en) | 1995-08-18 | 1997-03-06 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
EP1717248A1 (en) | 1997-06-04 | 2006-11-02 | Oxford Biomedica (UK) Limited | Tumor targeted vector |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
ATE220558T1 (de) * | 1997-11-22 | 2002-08-15 | Roche Diagnostics Gmbh | Verbessertes verfahren zur stabilisierung von proteinen |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US7198789B2 (en) | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
US6281336B1 (en) * | 1998-06-09 | 2001-08-28 | Statens Serum Institut | Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
EP2042598A1 (en) | 1998-11-18 | 2009-04-01 | Oxford Biomedica (UK) Limited | 5T4 tumour-associated antigen for use in tumour immunotherapy |
WO2000034317A2 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Method for reducing immunogenicity of proteins |
US7307161B1 (en) | 1999-04-28 | 2007-12-11 | Genetics Institute, Llc | Human Gil-19/AE289 polynucleotides |
US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
JP2003515323A (ja) | 1999-11-18 | 2003-05-07 | オックスフォード バイオメディカ(ユーケイ)リミテッド | 抗 体 |
DE60106394T3 (de) | 2000-02-24 | 2013-07-25 | Washington University St. Louis | Humanisierte antikörper, die amyloid beta peptid sequestrieren |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US7638604B2 (en) | 2001-02-23 | 2009-12-29 | Genetics Institute, Llc | Monoclonal antibodies against interleukin-22 |
AU2002258808A1 (en) | 2001-04-30 | 2002-11-11 | Eli Lilly And Company | Humanized antibodies |
ATE409047T1 (de) | 2001-04-30 | 2008-10-15 | Lilly Co Eli | Humanisierte antikörper |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
PL224001B1 (pl) | 2002-05-02 | 2016-11-30 | Wyeth Corp | Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie |
GB0215287D0 (en) | 2002-07-02 | 2002-08-14 | Oxford Biomedica Ltd | 5T4 antigen expression |
US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
RU2332986C2 (ru) * | 2003-04-04 | 2008-09-10 | Дженентек, Инк. | Высококонцентрированные композиции антител и белков |
PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
BRPI0515113A (pt) | 2004-09-10 | 2008-07-01 | Wyeth Corp | anticorpos anti-5t4 humanizados e conjugados de anticorpo anti-5t4/caliqueamicina |
CA2665423A1 (en) | 2006-10-12 | 2008-04-17 | Wyeth | Methods and compositions with reduced opalescence |
-
2007
- 2007-10-12 CA CA002665423A patent/CA2665423A1/en not_active Abandoned
- 2007-10-12 US US11/974,312 patent/US7744890B2/en not_active Expired - Fee Related
- 2007-10-12 MX MX2009003542A patent/MX2009003542A/es not_active Application Discontinuation
- 2007-10-12 CN CNA2007800368948A patent/CN101522219A/zh active Pending
- 2007-10-12 RU RU2009111138/15A patent/RU2009111138A/ru not_active Application Discontinuation
- 2007-10-12 AU AU2007308145A patent/AU2007308145A1/en not_active Abandoned
- 2007-10-12 JP JP2009532451A patent/JP2010506839A/ja active Pending
- 2007-10-12 BR BRPI0719250-9A patent/BRPI0719250A2/pt not_active IP Right Cessation
- 2007-10-12 WO PCT/US2007/021904 patent/WO2008045563A2/en active Application Filing
- 2007-10-12 KR KR1020097009757A patent/KR20090069330A/ko not_active Application Discontinuation
- 2007-10-12 EP EP07852729A patent/EP2076287A2/en not_active Withdrawn
-
2009
- 2009-03-24 IL IL197778A patent/IL197778A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2665423A1 (en) | 2008-04-17 |
WO2008045563A9 (en) | 2008-08-14 |
WO2008045563A2 (en) | 2008-04-17 |
BRPI0719250A2 (pt) | 2015-06-16 |
WO2008045563A3 (en) | 2008-06-19 |
IL197778A0 (en) | 2011-08-01 |
RU2009111138A (ru) | 2010-11-20 |
KR20090069330A (ko) | 2009-06-30 |
CN101522219A (zh) | 2009-09-02 |
US7744890B2 (en) | 2010-06-29 |
US20080154023A1 (en) | 2008-06-26 |
JP2010506839A (ja) | 2010-03-04 |
AU2007308145A1 (en) | 2008-04-17 |
EP2076287A2 (en) | 2009-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009003542A (es) | Metodos y composiciones con opalescencia reducida. | |
MX2007008790A (es) | Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso. | |
EA200801460A1 (ru) | Рекомбинантные моновалентные антитела и способы их получения | |
WO2010034032A3 (en) | Methods for preparing purified polypeptide compositions | |
PH12013502192A1 (en) | Antibodies against human angiopoietin 2 | |
WO2007131072A3 (en) | Hydrolytically-resistant boron-containing therapeutics and methods of use | |
WO2008070692A8 (en) | Bicyclic compounds and use as antidiabetics | |
WO2009002947A3 (en) | Compounds and peptides that bind the trail receptor | |
TW200732340A (en) | Novel forms of tiotropium bromide and processes for preparation thereof | |
WO2008132229A3 (en) | Highly concentrated insulin solutions and compositions | |
WO2009130198A3 (en) | Hyperglycosylated human coagulation factor ix | |
TW200716646A (en) | (S)-N-methylnaltrexone | |
HK1123733A1 (en) | Viral hepatitis treatment | |
NO20091509L (no) | Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter | |
TNSN07360A1 (en) | Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof | |
EA201170753A1 (ru) | Налмефена гидрохлорид дигидрат | |
WO2008048589A3 (en) | Compounds and methods for treatment of hcv | |
SI1969127T1 (sl) | Metoda pridobivanja biološko aktivnih proteinov, odvisnih od vitamina K, z rekombinantnimi metodami | |
EA201170703A1 (ru) | Производные адамантилбензамида | |
AU2009331669A8 (en) | Dihydropyridone amides as P2X7 modulators | |
WO2009090237A3 (en) | Fungicide hydroximoyl-tetrazole derivatives | |
UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
JO2721B1 (en) | Derivatives of artemisia plant and its preparations and therapeutic applications | |
EA200701648A1 (ru) | Замещённые пирролы и имидазолы, содержащие их композиции, способ получения и применение | |
JO2682B1 (en) | Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
FA | Abandonment or withdrawal |